Bharat Biotech launches nasal vaccine iNCOVACC

iNCOVACC will be the world’s first COVID-19 booster dose. It will give India more options to choose from when it comes to third doses or precautionary doses

Omicron BF7: 5 foreigners at Dalai Lama event in Gaya test positive

Health workers at the Gaya airport say that hordes of people are landing to attend the Buddhist event but only a handful are agreeing to get tested.

Yogi Adityanath proposes housing scheme for journalists

A panel of editors will set the criterion for eligibility, said the UP CM. Additionally, he gave away Rs 10 lakh to the families of 53 journalists who died of COVID-19.

Leaked! 250 million Covid cases in 20 days, say Chinese health officials notes

A senior Chinese journalist vouched for the veracity of the document on Radio Free Asia on Thursday. He said the documents were bonafide and  had been leaked by someone who attended the meeting keeping in mind public interests.

Pre-Diwali COVID Scare: Omicron’s BQ.1 Subvariant Detected in Pune

In a major health scare, the first case of Omicron’s BQ.1 subvariant was detected in Pune on Monday.

EXPLAINED: New Cricket Rules Which Will Come Into Force From October 1

The Marylebone Cricket Club made a few changes to its Code of Laws pertaining to international cricket in March, which will come into effect from October 1, 2022.

Bharat Biotech Completes Phase III Trial Of Intranasal Covid Vaccine

Bharat Biotech International Limited (BBIL) on Monday said that it has completed the phase III trials and booster doses for the Covaxin Intranasal Covid-19 vaccine.

Be Alert Against Covid, Monkeypox: Raj Health Min 

JAIPUR: Ringing the warning bell against COVID and Monkeypox viruses, Rajasthan Health minister Parsadi Lal Meena on Wednesday directed the officials to be vigilant against the two. Calling for an extensive sampling of seasonal diseases, Meena said that patients with fever, cough and cold should also be tested for Covid. For the prevention of seasonal

Bharat Biotech Partners With 2 Others For ‘Variant-Proof’ Covid Vaccine

NEW DELHI: India’s Bharat Biotech, Switzerland’s ExcellGene SA and University of Sydney have come together to manufacture a “variant-proof” Covid-19 vaccine. The SARS-CoV-2 vaccine candidate will be developed under the recently-approved consortium funding through the Coalition for Epidemic Preparedness Innovations (CEPI). Under this initiative, CEPI will provide funding up to USD 19.3 million for phase